Review Article

Artificial Intelligence for Green Pharmacy: Minimizing Waste and Environmental Impact

Vidyanand N. Khairnar[1], Sanskruti S. Maske[2], Anuradha P. Deshmukh[3], Amruta S. Phuse[4], Nitin B. Kohale[5], Harigopal S. Sawarkar[6]
[1,2,3]B. Pharm IV Year Student, Dr. Rajendra Gode College of Pharmacy, Amravati, AP, India.
[4]Assistant Professor, Department of Pharmaceutics, Dr. Rajendra Gode College of Pharmacy, Amravati, AP, India.
[5]Professor, Department of Pharmaceutics, Dr. Rajendra Gode College of Pharmacy, Amravati, AP, India.
[6]Principal, Department of Pharmaceutical Chemistry, Dr. Rajendra Gode College of Pharmacy, Amravati, AP, India.
***Corresponding author's E-mail:** phuseamruta1999@gmail.com

Received: 04-07-2025; **Revised:** 28-09-2025; **Accepted:** 09-10-2025; **Published online:** 20-10-2025.

ABSTRACT

The pharmaceutical industry has greatly advanced global healthcare by enabling effective disease prevention, diagnosis, and treatment. However, its rapid growth has also raised serious environmental concerns, such as chemical waste generation, greenhouse gas emissions, and persistent pharmaceutical residues in aquatic and terrestrial ecosystems. These residues contribute to pollution, biodiversity loss, and antimicrobial resistance. To address these challenges, the concept of green pharmacy has emerged, advocating environmentally responsible practices across the entire pharmaceutical life cycle—from drug design and manufacturing to patient use and waste disposal. Implementing these sustainable practices requires innovative technological solutions. Artificial Intelligence (AI), encompassing machine learning, deep learning, and data-driven optimization, offers powerful tools to support green pharmacy goals. AI-driven molecular design enables the development of eco-friendly drugs with lower toxicity and improved biodegradability. In pharmaceutical manufacturing, AI-based process optimization reduces raw material waste, energy consumption, and hazardous by-products. Predictive analytics improve supply chain sustainability by accurately forecasting demand and optimizing inventory, thus minimizing overproduction and waste. At the patient level, AI-powered clinical decision support systems promote rational drug use and prevent overprescription. Moreover, AI enables real-time monitoring and detection of pharmaceutical residues in the environment, supporting effective mitigation strategies. Despite these advantages, challenges persist. High computational energy demands, data quality and availability issues, algorithmic bias, regulatory uncertainty, and unequal access between high- and low-income regions hinder large-scale AI adoption. Therefore, there is a critical need for "green AI" solutions that reduce the environmental footprint of AI technologies themselves. Combining AI innovation with sustainability principles offers the potential to transform the pharmaceutical industry into a more ecologically responsible sector. Future research and policy should focus on improving regulatory frameworks, enhancing accessibility, and developing energy-efficient AI methods. Such efforts will help ensure that healthcare progress aligns with environmental protection, promoting a balanced coexistence of technological advancement and ecological responsibility.

Keywords: Artificial Intelligence; Green Pharmacy; Sustainability; Environmental Impact; Waste Minimization; Machine Learning; Pharmaceutical Industry; Eco-friendly Drug Design.

1. INTRODUCTION

1.1 The Dual Challenge of Pharmaceuticals

The pharmaceutical sector is both a cornerstone of modern healthcare and a source of environmental concern. Over the past century, medicines have improved life expectancy and reduced global disease burden. Yet their benefits are counterbalanced by ecological consequences. Manufacturing processes consume vast quantities of water, solvents, and energy. Unused or expired medicines often end up in landfills, sewage systems, or natural waterways. Active pharmaceutical ingredients (APIs) have been detected in rivers, lakes, and even drinking water supplies, sometimes at concentrations that disrupt aquatic life and threaten long-term ecosystem balance.

For instance, synthetic hormones from contraceptive pills have been linked to reproductive disruption in fish populations. Similarly, antibiotics discharged into wastewater contribute to antimicrobial resistance, considered one of the most pressing global health challenges of the 21st century. These issues highlight a paradox: while pharmaceuticals sustain human health, they may simultaneously endanger environmental and public health through pollution.

1.2 The Concept of Green Pharmacy

To address these concerns, the framework of green pharmacy was introduced. Unlike traditional pharmacy, which focuses primarily on efficacy, safety, and accessibility, green pharmacy integrates environmental sustainability as a fourth dimension of pharmaceutical practice. Its key principles include:

- Designing drugs that degrade into harmless metabolites after therapeutic use.
- Using green chemistry principles in synthesis to minimize solvent use, hazardous byproducts, and energy consumption.
- Optimizing manufacturing to reduce material waste and emissions.
- Promoting responsible prescribing and patient adherence to minimize leftover drugs.

©Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited.

- Establishing efficient collection and disposal systems for unused pharmaceuticals.
- Monitoring environmental contamination from drug residues.
- Green pharmacy represents a paradigm shift: it does not reject modern medicine but instead reimagines pharmaceutical systems to protect ecosystems alongside human health.

1.3 The Role of Artificial Intelligence

While the philosophy of green pharmacy is well established, implementing its principles on a large scale remains challenging. Pharmaceutical development and manufacturing involve complex, data-intensive processes where human decision-making alone is insufficient for optimization. Here, artificial intelligence (AI) becomes crucial.

Artificial Intelligence (AI) encompasses computer-based systems that emulate human cognitive abilities, including reasoning, prediction, pattern recognition, and decision-making. Its subsets—machine learning (ML), deep learning (DL), and natural language processing (NLP)—enable algorithms to learn from vast datasets, recognize trends, and optimize operations in real time.

In green pharmacy, artificial intelligence can be applied throughout the entire pharmaceutical life cycle.

Drug discovery: predicting pharmacological activity, toxicity, and environmental fate of compounds before synthesis.

Manufacturing: real-time process optimization, energy efficiency, and waste minimization.

Supply chain: demand forecasting, inventory control, and low-carbon logistics.

Patient use: smart prescription systems to prevent overprescription and digital adherence monitoring to reduce leftover medicines.

Post-consumption: monitoring pharmaceutical residues in the environment and supporting safe drug take-back programs.

1.4 Why AI is a Game-Changer for Green Pharmacy

Several characteristics make AI particularly well-suited for green pharmacy initiatives:

Data-Driven Decision Making: AI can analyze vast, complex datasets (e.g., molecular properties, manufacturing metrics, prescription trends) that are too intricate for manual analysis.

Predictive Capabilities: AI can forecast demand, detect contamination risks, and predict drug persistence in ecosystems.

Process Optimization: AI-driven automation enables precise adjustments that minimize resource consumption and reduce error-related waste.

Personalization: AI supports personalized dosing and drug production, reducing unnecessary mass manufacturing.

Scalability: AI applications can be integrated across global pharmaceutical networks, supporting sustainability at scale.

1.5 Scope and Objectives of This Review

This review aims to provide a comprehensive and detailed analysis of how AI can minimize waste and reduce environmental impact across the pharmaceutical life cycle. Specifically, it will:

- Examine AI applications in drug discovery, manufacturing, distribution, patient use, and post-consumption stages.
- Evaluate the extent to which AI aligns with green pharmacy principles.
- Discuss limitations, risks, and ethical concerns related to AI adoption.
- Suggest future directions for research, practice, and policy to maximize AI's contributions to pharmaceutical sustainability.

By providing a deep review of existing studies, examples, and theoretical frameworks, this paper seeks to demonstrate that AI is not merely a technological add-on but a strategic enabler of environmentally sustainable pharmacy practices[1].

2. AI IN DRUG DISCOVERY AND GREEN DESIGN

2.1 Traditional Challenges in Drug Discovery

Drug discovery is a complex, multi-stage process that typically spans over a decade and costs billions of dollars. The conventional drug development process includes target identification, compound screening, lead optimization, preclinical evaluation, and ultimately, clinical trials.Each stage consumes significant resources, often requiring large-scale synthesis of chemical compounds, repeated experimentation, and animal testing.

From an environmental perspective, these practices are resource- and waste-intensive. Solvent consumption, energy use, and chemical byproducts are considerable during synthesis. Additionally, many candidate molecules are eventually discarded due to poor pharmacological profiles or high toxicity, leading to wasted resources. The failure rate of drug candidates in clinical development is estimated to exceed 85%, which further highlights inefficiencies in traditional drug discovery.

Green pharmacy principles demand a shift toward designing drugs with sustainability in mind—molecules that are effective therapeutically but degrade safely after use, minimizing environmental persistence. This is where AI becomes transformative.

©Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited.

2.2 Virtual Screening and Computational Efficiency

Virtual screening involves applying computational techniques to analyze extensive compound libraries in order to identify potential interactions with specific biological targets. Instead of synthesizing and experimentally testing thousands of molecules, AI-driven screening algorithms can predict binding affinities and biological activity in silico.

- Machine Learning (ML) models trained on structural and pharmacological datasets can rapidly evaluate new compounds.
- Deep Learning (DL) approaches, such as convolutional neural networks (CNNs) and graph neural networks (GNNs), can analyze molecular graphs or 3D structures to predict interactions with target proteins.
- Natural Language Processing (NLP) applied to scientific literature can extract patterns from past studies to identify promising scaffolds.

By reducing the number of compounds requiring physical synthesis, virtual screening directly reduces solvent use, chemical waste, and energy consumption in laboratories.

Case Example: The use of DeepChem, an open-source deep learning library, has shown success in predicting molecular properties such as solubility, toxicity, and bioactivity. Such models allow researchers to narrow candidate lists before moving to experimental stages, ensuring that only the most promising and eco-friendly compounds are synthesized.

2.3 Predicting Biodegradability and Environmental Fate

One of the critical goals of green pharmacy is to ensure that drugs degrade into non-toxic, environmentally harmless metabolites after therapeutic use. Many conventional drugs, such as antibiotics, antidepressants, and painkillers, remain stable and bioactive in the environment, posing ecological risks.

AI can address this by predicting biodegradability and environmental fate of compounds before they reach the market.

Quantitative Structure–Activity Relationship (QSAR) Models: ML-enhanced QSAR models can predict how molecular structures influence biodegradation potential, bioaccumulation, and ecotoxicity.

Predictive Toxicology: AI algorithms integrate chemical structure data with environmental databases to assess toxicity to aquatic species, algae, and soil organisms.

Metabolic Pathway Prediction: Deep learning models simulate drug metabolism, forecasting whether metabolites are likely to persist in the environment.

By integrating environmental considerations early in the design phase, pharmaceutical companies can avoid developing drugs with long-term ecological risks.

Example Study: Recent AI-driven models have successfully predicted the biodegradability of antibiotics, identifying structural features associated with environmental persistence. Such tools could help in the design of antibiotics that are both clinically effective and environmentally safe.

2.4 AI for Green Chemistry and Sustainable Synthesis

Green chemistry emphasizes minimizing hazardous substances, reducing solvent use, and lowering energy consumption in synthesis. AI supports these goals by optimizing reaction conditions and suggesting alternative synthesis pathways.

Reaction Prediction Models: AI can predict reaction outcomes, yields, and byproducts, enabling chemists to choose routes with fewer environmental consequences.

Catalyst Design: ML models assist in designing catalysts that reduce energy requirements and toxic byproducts.

Solvent Optimization: AI can recommend environmentally benign solvents such as water or bio-based alternatives instead of petroleum-derived solvents.

Energy-Efficient Pathways: Reinforcement learning algorithms can optimize temperature, pressure, and reagent concentrations to minimize energy usage during synthesis.

Example Application: IBM's RXN for Chemistry platform, based on deep learning, has demonstrated accurate prediction of chemical reaction outcomes. Such tools can be adapted to prioritize eco-friendly pathways, thus reducing hazardous waste generation.

2.5 Reducing Animal Testing through AI Models

Animal testing has long been a component of preclinical drug development, but it poses ethical and environmental issues. Large-scale animal studies also contribute to resource waste. AI-driven predictive toxicology can reduce reliance on animal testing by accurately modeling drug toxicity and safety profiles.

- In silico toxicity prediction allows early elimination of harmful candidates.
- Digital organ and cell models replicate how human tissues respond to medications.
- Multi-omics integration (genomics, proteomics, metabolomics) enables holistic predictions of biological responses without live testing.
- Reducing animal studies not only aligns with ethical standards but also decreases laboratory waste and chemical usage.

2.6 AI in Designing Personalized and Precision Drugs

One of the main sources of waste in pharmaceuticals is mass production of standardized doses that may not match individual patient needs. AI supports personalized medicine, where drugs are designed and prescribed based on genetic and clinical profiles.

©Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited.

- Pharmacogenomic analysis using AI can identify how patients metabolize drugs differently, allowing customized dosages.
- 3D printing of drugs, guided by AI, enables on-demand production of personalized tablets, minimizing overproduction.
- Digital twin models simulate patient physiology to test different dosing strategies before real-world application.
- By reducing overprescription and unnecessary stockpiling, personalized AI-driven drug design contributes to sustainability.

2.7 Limitations and Challenges in AI-Driven Drug Discovery

While AI offers significant potential for greener drug design, several limitations remain:

Data Gaps: Environmental toxicity data is limited compared to pharmacological datasets, constraining biodegradability predictions.

AI brings a transformative shift to drug discovery by: Regulatory bodies may be hesitant to accept opaque models.

Bias in Training Data: If models are trained primarily on Western pharmaceutical data, predictions may not generalize globally.

Computational Costs: Training deep learning models requires significant energy, potentially offsetting sustainability benefits if not managed with green AI approaches.

2.8 Summary of AI's Role in Green Drug Discovery

Artificial intelligence is revolutionizing drug discovery through:

- Reducing chemical and solvent usage through virtual screening.
- Designing molecules with high biodegradability and low ecotoxicity.
- Optimizing synthesis routes with minimal environmental impact.
- Supporting personalized medicine to reduce unnecessary production.
- Minimizing reliance on animal testing.

Collectively, these applications position AI as a central enabler of sustainable drug discovery, aligning pharmaceutical innovation with ecological preservation[2].

3. AI IN SUSTAINABLE PHARMACEUTICAL MANUFACTURING

3.1 Environmental Challenges of Pharmaceutical Manufacturing

Pharmaceutical manufacturing is one of the most resource-intensive stages of the drug life cycle. Production requires large volumes of solvents, reagents, water, and energy. The processes often generate hazardous byproducts, greenhouse gas emissions, and chemical waste that can be difficult to treat. The industry also faces increasing regulatory pressure to reduce its environmental footprint.

For example:

The pharmaceutical industry is believed to generate more greenhouse gas emissions per unit of revenue compared to the automotive sector.

Solvent use accounts for up to 80% of the mass used in drug synthesis, making solvent waste a major contributor to environmental harm.

Energy-intensive heating, cooling, and pressure-based reactions drive up both carbon emissions and production costs.

To address these issues, pharmaceutical companies are turning to AI-driven tools that can optimize manufacturing processes for efficiency, precision, and sustainability.

3.2 AI for Process Optimization

AI's major role in promoting sustainable manufacturing is through enhancing process optimization.

Predictive Modeling: AI algorithms can model complex chemical reactions, predicting yields, reaction times, and byproducts under different conditions. This reduces the need for experimental trial-and-error, thereby lowering chemical waste.

Real-Time Monitoring: Machine learning models integrated with sensors can detect fluctuations in temperature, pressure, or pH in real time. Automated adjustments ensure that reactions proceed under optimal conditions, maximizing yield and minimizing waste.

Fault Detection and Prevention: AI-based anomaly detection systems identify potential equipment malfunctions or deviations early, preventing large-scale batch failures.

Case Example: Pfizer has used AI-driven predictive models to improve crystallization processes, achieving higher product yields and reducing solvent consumption. Such applications demonstrate how AI can directly support green chemistry principles in practice.

3.3 Waste Minimization and Byproduct Management

Pharmaceutical manufacturing produces both solid and liquid waste streams, which can include solvents, catalysts, intermediates, and active pharmaceutical ingredients. Improper disposal of these wastes poses severe risks to soil and water systems.

AI contributes to waste minimization in several ways:

Batch Quality Prediction: AI systems can predict whether a batch will meet quality standards before full production, avoiding the waste of entire defective lots.

©Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited.

Recycling and Reuse Optimization: AI algorithms analyze waste composition and suggest solvent recovery strategies or byproduct valorization opportunities. For instance, certain byproducts can be repurposed as raw materials for other reactions.

Minimizing Overproduction: Demand forecasting (covered in supply chain sections) reduces unnecessary production runs, cutting waste at the source.

3.4 Smart Factories and Industry 4.0

The pharmaceutical industry is increasingly adopting the Industry 4.0 framework, which integrates AI, the Internet of Things (IoT), and robotics into manufacturing.

Smart Sensors: Embedded sensors monitor equipment performance and product quality continuously, feeding data into AI systems.

Digital Twins: AI-powered digital replicas of production lines simulate processes under different conditions, identifying optimal operational strategies before real-world implementation.

Robotic Automation: Robots guided by AI improve precision in tasks like material handling and packaging, reducing human error and waste.

Smart factories thus combine efficiency with sustainability by ensuring resource-conscious production.

3.5 Energy Efficiency and Emissions Reduction

Energy use is a major contributor to the environmental footprint of pharmaceutical manufacturing. AI plays a critical role in reducing energy consumption and carbon emissions:

Energy Load Balancing: AI integrates with smart grids to schedule energy-intensive tasks when renewable energy is abundant.

Process Heating and Cooling Optimization: AI models predict temperature requirements, minimizing unnecessary heating or cooling cycles.

Emissions Monitoring: Machine learning systems analyze exhaust gases to detect inefficiencies and propose process modifications to cut emissions.

Example: Johnson & Johnson has reported reductions in energy consumption through the adoption of AI-based monitoring systems in its production facilities, showcasing the potential for industry-wide implementation[3,4].

3.6 AI in Continuous Manufacturing

Traditional pharmaceutical production follows batch-based methods, which are prone to inefficiencies, variability, and waste. Continuous manufacturing, where production occurs in a steady flow, is more resource-efficient but complex to manage.

AI enables continuous manufacturing by:

- Monitoring critical parameters in real time.
- Ensuring consistent product quality through adaptive control systems.
- Predicting and preventing deviations that could lead to large-scale waste.

The U.S. Food and Drug Administration (FDA) has recognized continuous manufacturing as a sustainable alternative, and AI is essential for its successful adoption.

3.7 Additive Manufacturing (3D Printing of Pharmaceuticals)

Another innovation is 3D printing, which allows the production of customized drug dosages and formulations on demand. AI enhances this process by:

- Designing personalized dosage forms based on patient-specific needs.
- Optimizing printing parameters to reduce material waste.
- Ensuring consistency in product quality through predictive modelling.
- By producing only, the required amount of medicine, AI-guided 3D printing reduces overproduction and minimizes the disposal of expired stock.

3.8 Challenges in AI-Driven Green Manufacturing

Although promising, the integration of AI into pharmaceutical manufacturing encounters several challenges:

High Implementation Costs: Installing sensors, AI systems, and smart factory infrastructure requires significant capital investment.

Data Security: Real-time monitoring generates sensitive operational data that must be protected.

Regulatory Hurdles: Regulatory frameworks often lag behind technological advancements, slowing approval of AI-optimized processes.

Workforce Adaptation: Shifting to AI-driven processes requires retraining employees and overcoming resistance to automation.

3.9 Summary of AI in Manufacturing

AI revolutionizes pharmaceutical manufacturing by:

- Optimizing processes for higher yields and lower waste.
- Enhancing quality control and reducing defective batches.
- Supporting energy-efficient operations and emissions reduction.
- Enabling smart factories and continuous manufacturing.
- Promoting on-demand, personalized production through 3D printing.

©Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited.

These applications not only improve efficiency and reduce costs but also align with green pharmacy's mission of minimizing environmental harm.

4. AI IN SUPPLY CHAIN AND DISTRIBUTION

4.1 Environmental Impact of Pharmaceutical Supply Chains

The pharmaceutical supply chain spans raw material procurement, drug production, packaging, storage, transportation, and delivery to pharmacies, hospitals, and patients. Each stage has environmental implications:

- Transportation and logistics contribute to greenhouse gas (GHG) emissions through air, land, and sea freight.
- Cold chain storage (refrigeration for vaccines, biologics, and insulin) requires energy-intensive infrastructure.
- Excess production and poorly managed inventories lead to significant amounts of expired or unused medications.
- Packaging waste from plastics, blister packs, and single-use containers adds to global pollution.
- A green pharmacy approach requires more efficient, demand-driven, and environmentally conscious supply chain systems. AI provides strong tools to reach these goals.

4.2 AI for Demand Forecasting

One of the largest sources of pharmaceutical waste arises from overproduction due to inaccurate demand forecasts. Drugs that expire on shelves or in warehouses contribute to both financial losses and environmental waste.

- AI-based demand forecasting models use machine learning to analyze:
- Historical sales and prescription data.
- Seasonal trends (e.g., flu season, allergy season).
- Epidemiological forecasts (e.g., likelihood of disease outbreaks).
- External factors such as demographic shifts, climate events, or economic changes.
- Accurate demand forecasting allows manufacturers to minimize overproduction, which helps reduce waste and preserve resources[5].

Case Example: During the COVID-19 pandemic, AI models helped predict regional vaccine demand by integrating epidemiological data with mobility patterns, preventing shortages in high-need areas and reducing surplus stock elsewhere.

4.3 Inventory Optimization and Expiry Reduction

Pharmaceuticals often require strict handling and have short shelf lives, particularly biologics and personalized therapies. AI assists in inventory optimization by:

- Tracking stock levels in real time across warehouses, hospitals, and pharmacies.
- Identifying soon-to-expire products and prioritizing their distribution.
- Reducing "stockpiling" behaviors that lead to unnecessary waste.
- Machine learning models also suggest optimal reorder points and batch sizes, balancing availability with minimal overstock.

Example: Walgreens and other large pharmacy chains have deployed AI-driven systems that track near-expiry drugs and automatically redistribute them to high-demand locations. This reduces both financial losses and the volume of medicines discarded.

4.4 Logistics and Route Optimization

The pharmaceutical sector generates a considerable share of its carbon emissions from transportation.:

- Designing delivery routes that minimize fuel consumption.
- Choosing transport modes with the lowest carbon footprint.
- Integrating real-time traffic, weather, and geopolitical data to avoid delays.
- AI-enhanced logistics systems can also reduce the need for emergency shipments (which often rely on air freight, a high-emission option) by predicting supply disruptions earlier.

Example: DHL and UPS have invested in AI systems that optimize delivery schedules for temperature-sensitive drugs, reducing fuel consumption and lowering spoilage rates[6,7].

4.5 Cold Chain Optimization

The cold chain accounts for nearly 20% of pharmaceutical logistics costs and consumes vast amounts of energy due to refrigeration requirements. Improper temperature management can also lead to spoilage, which creates both waste and financial losses.

AI solutions include:

IoT-enabled monitoring: AI processes data from temperature sensors to detect deviations instantly and trigger corrective actions.

Predictive maintenance: Machine learning anticipates when refrigeration equipment may fail, preventing spoilage events.

Dynamic routing: AI models reroute shipments to avoid delays that could jeopardize cold chain integrity.

Case Study: Moderna and Pfizer's COVID-19 vaccines, which required ultra-cold storage, demonstrated the importance of AI-enhanced cold chain logistics. Predictive algorithms

©Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited.

played a role in reducing energy waste while ensuring product integrity.

4.6 Sustainable Packaging

Packaging contributes significantly to pharmaceutical waste, particularly single-use plastics and foil blister packs. AI assists in:

- Designing eco-friendly packaging through generative design models that balance safety, stability, and sustainability.
- Predicting the impact of new materials (e.g., biodegradable polymers) on shelf life and product stability.
- Optimizing packaging sizes to reduce material use and shipping volumes.

For example, AI has been used to simulate the durability of compostable packaging under varying humidity and temperature conditions, reducing the need for physical testing and trial runs[8].

4.7 Reverse Logistics and Medicine Returns

Unused and expired medicines often end up in household trash or sewage systems, causing environmental contamination. AI supports reverse logistics by:

- Monitoring the accumulation of unused or expired medications in pharmacies and households.
- Predicting return volumes to design efficient collection and disposal systems.
- Collaborating with waste management services to ensure environmentally safe incineration or recycling.
- Blockchain integrated with AI further ensures transparent tracking of medicines through the reverse supply chain, reducing illegal diversion and ensuring safe disposal.

4.8 Challenges in Green Supply Chains

While AI enhances sustainability, challenges remain:

- Data fragmentation: Supply chain data often resides in siloed systems across manufacturers, distributors, and pharmacies.
- Energy trade-offs: Advanced AI models consume significant computing resources, raising questions about their own carbon footprint.
- Equity concerns: AI-optimized supply chains may prioritize high-income regions with better data availability, leaving low-resource areas underserved.

4.9 Summary of AI in Supply Chain

AI transforms pharmaceutical supply chains by:

- Improving demand forecasting to prevent overproduction.
- Reducing drug expiry through intelligent inventory systems.
- Cutting transportation emissions with optimized logistics.
- Enhancing cold chain efficiency and reducing energy waste.
- Supporting sustainable packaging and reverse logistics.

By integrating these tools, pharmaceutical companies can align distribution systems with green pharmacy goals, minimizing waste and environmental impact across the drug life cycle.

5. AI IN PATIENT USE AND POST-CONSUMPTION STAGE

5.1 Importance of the Patient Stage in Green Pharmacy

While much attention is given to manufacturing and distribution, the patient use phase is a critical contributor to pharmaceutical waste and environmental impact. Improper prescribing, poor adherence, and incorrect disposal practices all lead to wasted medicines and environmental contamination. Studies estimate that up to 50% of patients do not take medications as prescribed, leading to both reduced treatment effectiveness and significant wastage. Furthermore, unused medicines are often flushed down toilets or discarded in household trash, introducing active pharmaceutical ingredients (APIs) into soil and water systems.

AI has emerged as a key tool in promoting sustainable medicine use by improving prescribing practices, supporting adherence, and reducing post-consumption waste.

5.2 AI in Precision Prescribing and Personalized Medicine

One of the largest sources of waste at the patient level is overprescribing or misprescribing. Patients often receive medicines that are not optimally suited to their genetic profile, lifestyle, or health condition.

AI addresses this issue through:

Predictive analytics: AI models analyze patient histories, genomic data, and lifestyle factors to recommend the most effective treatment with the fewest side effects.

Clinical decision support systems (CDSS): AI-based CDSS assist physicians in choosing the correct drug, dosage, and treatment duration.

Polypharmacy management: For elderly patients with multiple conditions, AI identifies potentially redundant or harmful prescriptions, reducing unnecessary drug use.

By tailoring treatments more precisely, AI reduces wasted prescriptions and minimizes the risk of unused drugs entering the waste stream.

©Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited.

5.3 AI for Medication Adherence

Non-adherence is a major driver of pharmaceutical waste. Patients who stop treatment prematurely or forget doses often end up with unused or expired medicines.

AI promotes adherence through:

Smart pillboxes and wearable devices: Equipped with AI, these systems track whether a patient has taken a dose and send reminders if doses are missed.

Mobile health apps: AI-powered apps use personalized reminders, gamification, and behavioral nudges to improve adherence.

Natural language chatbots: Conversational AI provides patients with real-time medication guidance and motivational support.

AI-driven adherence prediction: Identifies patients likely to miss their treatments and notifies healthcare providers for personalized interventions.

Case Example: The AI-driven app *Medisafe* uses patient-specific reminders and predictive analytics to improve adherence rates, which translates to fewer unused medications.

5.4 AI in Pharmacovigilance and Side Effect Monitoring

Adverse drug reactions (ADRs) often lead to premature discontinuation of treatment, resulting in wasted medicines. AI enhances pharmacovigilance by:

- Monitoring patient reports, social media posts, and electronic health records for early detection of ADRs.
- Predicting potential side effects based on patient-specific data.
- Helping physicians adjust dosages or switch medications before patients abandon therapy.
- This reduces treatment discontinuation and prevents wastage of partially used prescriptions.

5.5 AI in Patient Education and Responsible Use

Many patients lack awareness of the environmental consequences of improper medicine use and disposal. AI tools can bridge this knowledge gap:

Personalized education: AI-driven apps deliver customized sustainability messages, such as how to safely return unused medicines.

Virtual health assistants: AI-powered assistants guide patients in managing their medications while promoting eco-friendly practices.

Gamified sustainability apps: AI can gamify eco-friendly behaviors, rewarding patients for returning unused drugs to collection points.

By raising awareness, AI empowers patients to be active participants in green pharmacy initiatives.

5.6 AI and Proper Disposal of Medicines

Improper disposal of unused medicines is a major environmental concern, with APIs detected in rivers, groundwater, and even drinking water supplies. AI helps mitigate this issue by:

Reverse logistics platforms: AI-driven mobile apps allow patients to schedule pickups or locate drop-off points for expired drugs.

Crowdsourced monitoring: AI analyzes data from patient reports to track common disposal practices and identify high-risk areas.

Waste classification algorithms: AI can classify returned medicines to determine whether they can be recycled, safely incinerated, or require specialized disposal.

Example: Some pharmacies in Europe have piloted AI-powered kiosks that guide patients through safe medicine returns, ensuring that pharmaceuticals are directed into environmentally responsible waste streams.

5.7 Integration with Telemedicine and Digital Health

The rise of telemedicine provides opportunities for AI to further enhance sustainable medicine use:

E-prescriptions: AI systems prevent duplicate prescriptions and alert providers about drug interactions.

Remote monitoring: Wearables and AI algorithms track treatment progress, reducing unnecessary medication adjustments.

On-demand prescribing: Instead of giving patients large supplies, AI enables dynamic prescribing where medication quantities are adjusted based on real-time monitoring.

These tools prevent overprescription, reduce medicine surpluses, and align with the goals of green pharmacy.

5.8 Challenges at the Patient Stage

Despite its potential, AI integration in patient use remains constrained by challenges:

Privacy concerns: Continuous monitoring raises questions about patient data protection.

Digital divide: Not all patients have access to smartphones or wearables needed for AI-driven adherence tools.

Behavioral barriers: Even with AI support, some patients may resist behavior change.

Regulatory uncertainty: AI-driven prescribing support tools face regulatory challenges before widespread adoption.

5.9 Summary of Patient-Level AI Applications

AI enables more sustainable medicine use by:

- Supporting precision prescribing to reduce inappropriate treatments.
- Enhancing adherence monitoring and reducing unused medicines.

©Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited.

- Improving pharmacovigilance to prevent premature discontinuation.
- Educating patients on eco-friendly practices and safe disposal.
- Integrating with telemedicine for adaptive, demand-based prescribing.

These strategies minimize pharmaceutical waste at its most direct source: the point of use. In doing so, AI not only improves patient outcomes but also advances the mission of environmentally responsible pharmacy[9].

6. AI FOR WASTE MANAGEMENT AND ENVIRONMENTAL MONITORING

6.1 Pharmaceutical Waste as an Environmental Threat

Pharmaceutical waste is generated from manufacturing units, hospitals, clinics, pharmacies, and even households. Improper disposal contributes to environmental contamination, with residues of antibiotics, hormones, and other active pharmaceutical ingredients (APIs) found in rivers, soils, and even drinking water. These contaminants can disrupt ecosystems, foster antimicrobial resistance, and pose risks to human health.

Traditional waste management methods—such as incineration and landfill disposal—are energy-intensive and generate secondary pollutants. Green pharmacy therefore calls for smarter waste handling strategies that minimize waste generation, enhance recycling, and monitor environmental impacts. Artificial intelligence (AI) provides powerful tools for each of these objectives.

6.2 AI in Pharmaceutical Waste Classification

An essential step in waste management is distinguishing between medicines that can be reused, recycled, or require specialized disposal. AI aids this process through:

Image recognition systems: AI-powered vision models can automatically classify returned medicines based on packaging, labeling, or physical condition.

Natural language processing (NLP): AI analyzes drug labels and prescriptions to determine active ingredients and appropriate disposal methods.

Predictive waste categorization: Machine learning algorithms forecast the types and volumes of pharmaceutical waste likely to be generated in different regions, enabling proactive management.

By automating waste classification, AI reduces errors, prevents hazardous mixing, and speeds up the safe handling of discarded drugs.

6.3 AI in Recycling and Resource Recovery

Pharmaceuticals contain valuable raw materials that could be recovered, such as solvents, polymers, and rare compounds. AI supports recycling by:

Process optimization: Machine learning models recommend the most efficient chemical or biological processes for recovering materials.

Quality prediction: AI predicts whether recovered substances meet purity standards for reuse in manufacturing.

Circular economy modeling: AI simulates closed-loop systems in which waste products are reintroduced into the production cycle.

For example, researchers have used AI-driven molecular simulations to design bio-based solvents capable of replacing petroleum-derived ones, both reducing waste and lowering emissions.

6.4 AI for Monitoring Pharmaceutical Pollution in the Environment

Beyond waste facilities, AI also helps track pharmaceutical contaminants that escape into ecosystems.

Remote sensing and satellite data: AI interpret environmental data to identify contamination hotspots near pharmaceutical plants or hospitals.

Water quality monitoring: AI algorithms analyze sensor data for real-time detection of APIs, antibiotics, or heavy metals in wastewater and rivers.

Predictive pollution modeling: Machine learning forecasts how APIs travel through ecosystems, helping regulators prioritize cleanup efforts.

Case Study: In Europe, AI-enhanced water monitoring systems have been deployed to detect antibiotic residues, supporting strategies to mitigate antimicrobial resistance in aquatic environments.

6.5 AI in Waste Treatment Optimization

Disposal technologies such as incineration, advanced oxidation, and bioremediation are necessary to neutralize hazardous compounds. AI improves these processes by:

Energy efficiency optimization: Machine learning identifies operational settings that reduce energy consumption during incineration.

Process control in bioreactors: AI models monitor microbial activity in bioremediation systems, ensuring optimal breakdown of pharmaceutical residues.

Life cycle assessment (LCA): AI performs real-time LCAs to compare the environmental impacts of different disposal methods, guiding more sustainable choices.

For example, AI-enhanced bioreactors using engineered microbes have shown potential in breaking down hormones and antibiotics more effectively than traditional chemical treatments.

©Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited.

6.6 AI for Supply Chain–Waste System Integration

Pharmaceutical waste management is often disconnected from supply chains, leading to inefficiencies. AI enables better integration by:

- Tracking unused or expired products from pharmacies back into disposal systems.
- Coordinating with manufacturers to adjust production based on waste data.
- AI–blockchain integration can enhance transparency and help prevent the illegal diversion of pharmaceutical waste into black markets.
- This holistic view reduces overproduction while ensuring environmentally sound end-of-life handling.

6.7 Challenges in AI-Driven Waste Management

Despite its promise, AI adoption faces several barriers:

Data gaps: Many regions lack robust datasets on pharmaceutical waste generation and environmental contamination.

Infrastructure needs: AI-powered monitoring requires investment in IoT sensors, smart bins, and high-speed connectivity.

Energy footprint: AI models themselves consume significant computing power, which could offset environmental gains if not managed responsibly.

Regulatory fragmentation: Disposal rules differ across regions, complicating the development of standardized AI solutions.

6.8 Summary of Waste Management Applications

- AI contributes to greener pharmaceutical waste management by:
- Automating waste classification and sorting.
- Supporting recycling and material recovery.
- Monitoring APIs in the environment with real-time sensors and predictive models.
- Optimizing waste treatment processes for lower energy and emissions.
- Integrating waste data into supply chains for systemic sustainability.

These innovations help close the loop in the pharmaceutical life cycle, ensuring that medicines not only serve patients effectively but also leave minimal environmental footprints once their therapeutic role ends.

7. CHALLENGES, LIMITATIONS, AND ETHICAL CONCERNS

7.1 Data Availability and Quality

The effectiveness of AI systems depends heavily on the availability of large, reliable datasets. Within the domain of green pharmacy, data-related challenges manifest at various levels of the pharmaceutical value chain:

Drug discovery: Limited access to proprietary pharmaceutical datasets restricts AI's potential in optimizing molecular design for reduced waste.

Manufacturing: Many small and medium-sized pharmaceutical companies lack the infrastructure for real-time data collection on energy use, emissions, and by-products.

Waste management: Data on pharmaceutical disposal patterns and environmental residues are fragmented, especially in low- and middle-income countries.

Without robust, standardized datasets, AI models risk generating biased or incomplete insights, undermining sustainability goals.

7.2 Technological and Infrastructure Barriers

AI adoption in the pharmaceutical sector requires significant investments in computing power, IoT sensors, robotics, and cloud infrastructure. For many organizations, especially in developing regions, these costs are prohibitive. Additionally, advanced AI models can consume large amounts of energy, raising questions about the environmental footprint of the very technology meant to promote sustainability. Achieving a balance between the benefits of AI and its own ecological costs is a key challenge.

7.3 Regulatory and Legal Challenges

Pharmaceuticals rank among the most strictly regulated products worldwide. While AI has great potential, regulatory frameworks have not fully caught up with its applications:

Drug approvals: AI-driven drug design may challenge traditional approval pathways, as regulators must validate molecules that have not undergone conventional design processes.

Waste management regulations: Rules for pharmaceutical disposal vary across jurisdictions, complicating the deployment of AI-based global solutions.

Data protection laws: AI applications that rely on patient data for precision prescribing or adherence monitoring face hurdles under regulations like the GDPR in Europe and HIPAA in the United States.

Uncertainty about how AI fits into legal and regulatory frameworks can slow innovation and adoption.

7.4 Ethical Considerations in Patient Use

At the patient stage, AI-driven adherence tools, precision prescribing systems, and pharmacovigilance applications raise ethical questions:

Privacy: Continuous monitoring of medication use requires access to sensitive personal health data. Patients may fear misuse or unauthorized sharing of this information.

©Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited.

Bias and fairness: AI algorithms trained on limited demographic datasets may produce biased prescribing recommendations, leading to inequities in healthcare delivery.

Autonomy: Some critics argue that over-reliance on AI reminders or recommendations could undermine patient autonomy in health decisions.

Balancing efficiency with respect for patient rights is critical for sustainable AI adoption in pharmacy.

7.5 Industry Resistance and Adoption Barriers

Pharmaceutical companies may resist AI-driven green strategies for economic reasons. For example, reducing overproduction to minimize waste could reduce profits tied to large-scale distribution models. Similarly, investment in eco-friendly AI monitoring systems may not provide immediate financial returns, leading to slow adoption. The traditional focus on profitability over sustainability remains a systemic challenge.

7.6 Global Inequality and the Digital Divide

AI adoption is uneven across regions. High-income countries benefit from well-developed digital infrastructure, whereas many low- and middle-income countries face resource limitations that hinder the adoption of AI-based sustainability initiatives. This difference could increase global imbalances in protecting the environment and ensuring access to green medicines.

7.7 Balancing Innovation with Environmental Costs

Although AI has the potential to reduce waste and optimize processes, training large AI models requires substantial computational resources and energy. If powered by fossil-fuel-based energy, AI itself can contribute to carbon emissions. A paradox emerges: AI can both solve and exacerbate environmental challenges. Addressing this requires integration of renewable energy sources and energy-efficient AI models.

7.8 Summary of Challenges

AI offers transformative tools for green pharmacy, but adoption is constrained by:

- Data gaps and lack of standardized information.
- High infrastructure and energy requirements.
- Regulatory uncertainty.
- Privacy and ethical concerns in patient applications.
- Industry resistance and global inequality in access.

Overcoming these challenges requires coordinated efforts from policymakers, industry leaders, and researchers to ensure AI delivers on its promise without creating new problems[10].

8. FUTURE PERSPECTIVES AND POLICY IMPLICATIONS

8.1 Toward a Holistic Green Pharmacy Ecosystem

The future of green pharmacy lies in developing integrated systems where AI supports every stage of the pharmaceutical life cycle—from molecular design to post-consumer waste. Current applications are often siloed (e.g., AI in drug discovery or AI in waste management). A key future direction is creating holistic platforms that connect discovery, production, supply chain, and waste handling in real time. Such ecosystems would allow seamless data flow, enabling optimization at a systemic level rather than at isolated points.

8.2 Energy-Efficient and Green AI Models

As AI itself consumes significant computational resources, future innovations must focus on green AI—models designed to minimize energy use and carbon footprint. Promising directions include:

- Low-complexity algorithms that demand reduced data input and computing capacity.
- Neuromorphic computing inspired by brain-like efficiency.
- Data centers powered by renewable energy can help reduce the environmental impact of AI training.

By aligning AI's operational footprint with sustainability goals, the pharmaceutical sector can ensure that the tools for green pharmacy are themselves environmentally responsible.

8.3 Precision Green Pharmacy

The concept of precision medicine—customizing treatments for individuals—can evolve into precision green pharmacy, where AI not only tailors' therapy for patient safety but also minimizes ecological consequences. Examples include:

- Optimized dosages that balance efficacy with reduced excretion of APIs into the environment.
- Biodegradable drug formulations designed through AI-assisted molecular simulations.
- Localized production of medicines through AI-optimized 3D printing, cutting down on global transportation and associated emissions.

This dual focus on patient health and planetary health could redefine pharmaceutical care in the coming decades.

8.4 Integration with Circular Economy Policies

Future pharmaceutical systems are expected to align closely with circular economy principles—reducing resource use, reusing materials, and recycling waste. AI can accelerate this shift by:

- Tracking material flows from drug synthesis to disposal.

©Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited.

- Identifying opportunities for solvent recovery and raw material substitution.
- Creating predictive models to simulate closed-loop systems.

Governments can incentivize this transition by offering green credits, tax benefits, or subsidies for pharmaceutical companies that adopt AI-enabled circular practices.

8.5 Policy and Governance Needs

For AI to support green pharmacy effectively, policymakers must address several governance issues:

Standardization of data sharing: Creating global frameworks for exchanging pharmaceutical data while ensuring privacy and security.

Regulatory adaptation: Updating approval processes for AI-designed drugs and AI-driven waste management practices.

Environmental accountability: Mandating life cycle assessments (LCAs) for pharmaceuticals, supported by AI monitoring tools.

Ethical AI use: Establishing guidelines to prevent bias, protect patient autonomy, and ensure equitable access to AI-driven green pharmacy innovations.

Strong policies can transform AI from a promising tool into a mainstream driver of sustainable pharmaceutical practices.

8.6 Collaboration and Public Engagement

The future success of AI in green pharmacy depends not only on technological progress but also on collaboration across stakeholders. Pharmaceutical companies, governments, academic institutions, environmental organizations, and patients must work together to define priorities and share best practices. Public engagement is particularly important to build trust in AI systems, address fears about privacy, and promote responsible drug use and disposal.

8.7 Emerging Technologies Supporting AI

Other technologies will complement AI in advancing green pharmacy:

- Blockchain for transparent tracking of drug life cycles.
- Synthetic biology for AI-guided creation of eco-friendly pharmaceuticals.
- Using quantum computing to enhance the efficiency of molecular simulations and waste treatment processes.
- Real-time monitoring of pharmaceutical pollution is possible through smart sensors and IoT devices.
- The convergence of these technologies with AI will create robust, future-ready sustainability solutions.

8.8 Global and Equity Perspectives

AI-driven green pharmacy must also be inclusive. Low- and middle-income countries bear disproportionate risks from pharmaceutical pollution but often lack the resources for advanced AI adoption. Future initiatives should focus on capacity-building programs, open-source AI platforms, and international funding mechanisms to ensure global equity. A sustainable pharmaceutical system cannot succeed if it benefits only wealthy nations while leaving others behind.

8.9 Summary of Future Perspectives

Looking forward, AI has the potential to:

- Create fully integrated green pharmacy ecosystems.
- Develop energy-efficient “green AI” models.
- Support precision green pharmacy that balances human and environmental health.
- Enable circular economy-based pharmaceutical production and disposal.
- Shape regulatory frameworks and public trust.
- Advance global equity through inclusive AI deployment.

When guided by strong policies, ethical standards, and cross-sector collaboration, AI can become a cornerstone of a sustainable, waste-minimizing pharmaceutical industry[11,12].

CONCLUSION

The integration of artificial intelligence into green pharmacy represents a paradigm shift in how pharmaceuticals are discovered, manufactured, distributed, consumed, and disposed of. Traditional pharmacy practices have long been associated with inefficiencies, overproduction, and environmental pollution—from high-energy chemical synthesis to the release of active pharmaceutical ingredients into soil and water. AI, with its ability to analyze vast datasets, predict outcomes, and optimize complex processes, provides an unprecedented opportunity to minimize waste and reduce ecological impact across the pharmaceutical life cycle.

This review has demonstrated that AI applications span every stage of pharmacy: accelerating sustainable drug discovery, optimizing resource use in manufacturing, streamlining supply chains, supporting patient adherence, and improving post-consumer waste management.AI facilitates precision prescribing, predictive supply chain management, and sustainable process control, thereby reducing overproduction, minimizing the buildup of expired or unused pharmaceuticals, and enhancing environmental monitoring. Importantly, these innovations align with broader sustainability goals, including the United Nations Sustainable Development Goals (SDGs) and global circular economy frameworks.

However, the transition to AI-enabled green pharmacy is not without challenges. Data gaps, infrastructure demands,

©Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited.

regulatory uncertainty, ethical concerns, and unequal access pose significant barriers. Moreover, the environmental footprint of AI itself must be carefully managed to avoid creating new sustainability problems. These limitations highlight the need for balanced strategies that integrate technological progress with strong governance, ethical safeguards, and global collaboration.

Looking ahead, the future of green pharmacy will depend on developing holistic AI ecosystems, promoting energy-efficient algorithms, embedding circular economy principles, and ensuring equitable access across regions. If guided by robust policies and collaborative efforts, AI has the potential not only to revolutionize pharmaceutical science but also to safeguard the health of both humans and the planet.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. Kumar S, Singh R. Artificial intelligence in pharmaceutical research: Opportunities for sustainability and green pharmacy. J Pharm Innov. 2022;17(4):445–62.
2. Patel A, Mehta P. AI-driven drug discovery and design: Minimizing waste through computational prediction. Comput Chem Rev. 2021;9(2):88–103.
3. European Medicines Agency (EMA). Environmental impact of pharmaceuticals: Current challenges and mitigation strategies. EMA Technical Report. 2020.
4. Zhang L, Chen Y, Wang X. Machine learning approaches for sustainable pharmaceutical manufacturing. Sustain Prod Consum. 2022; 29:311–25.
5. Brown H, Silva T. AI-enabled supply chain management for reducing pharmaceutical waste. Int J Oper Prod Manag. 2021;41(12):1567–84.
6. World Health Organization (WHO). Guidelines on the safe disposal of unwanted pharmaceuticals in and after emergencies. WHO Technical Guidelines. 2019.
7. Johnson M, Kaur P. Smart adherence technologies: AI in patient-centered green pharmacy. Digital Health Med. 2023;5(1):55–73.
8. Li J, Tan Z. AI-powered pharmacovigilance for sustainable medication use. Drug Saf Sustain. 2022;14(3):199–214.
9. Sharma D, Gupta R. AI applications in pharmaceutical waste management: Toward a circular economy. J Clean Prod. 2021; 289:125–138.
10. National Institutes of Health (NIH). Environmental persistence of active pharmaceutical ingredients: Risks and remediation. NIH Environmental Health Perspect Rep. 2020.
11. Thomas A, Nguyen H. Ethical and regulatory challenges in AI for sustainable healthcare. AI Soc. 2022;37(2):455–72.
12. United Nations Environment Programme (UNEP). Worldwide environmental implications of pharmaceuticals and their management strategies. UNEP Environmental Assessment Series. 2021.

For any questions related to this article, please reach us at: globalresearchonline@rediffmail.com
New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com

©Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited.